Search

for
Search:

GlossaryEtanercept (Enbrel)

biologic drug inhibiting TNF to reduce inflammation in autoimmune diseases

Etanercept is a biologic medication that works by inhibiting tumor necrosis factor (TNF), a substance in the body that causes inflammation. It is commonly used to treat autoimmune conditions like rheumatoid arthritis and psoriasis, where the immune system mistakenly attacks the body's own tissues.

Related Terms

Learn

0 / 0 results

— no results

Research

5 / 47 results

research Safety of Dermatologic Medications in Pregnancy and Lactation

159 citations, March 2014 in “Journal of The American Academy of Dermatology”

Some skin medications are safe during pregnancy and breastfeeding, but others can harm the baby and should be avoided.

research Recurrence of Alopecia Areata in a Patient Receiving Etanercept Injections

75 citations, June 2005 in “Archives of Dermatology”

Etanercept may not prevent alopecia areata from coming back.

research Safety of Dermatologic Medications in Pregnancy and Lactation

73 citations, March 2014 in “Journal of The American Academy of Dermatology”

Most dermatologic medications are safe during pregnancy and breastfeeding, but some should be avoided due to potential risks.

research Drugs and Hair Loss: Mechanisms and Clinical Implications

54 citations, September 2012 in “Dermatologic Clinics”

Some medications can cause hair loss, but stopping the drug usually leads to recovery within 3 months.

Alopecia Induced by Tumor Necrosis Factor-Alpha Antagonists: Description of 52 Cases and Disproportionality Analysis in a Nationwide Pharmacovigilance Database

research Alopecia Induced by Tumor Necrosis Factor-Alpha Antagonists: Description of 52 Cases and Disproportionality Analysis in a Nationwide Pharmacovigilance Database

26 citations, March 2014 in “Rheumatology”

Some drugs used to treat inflammation may cause hair loss.

View more "enbrel" in research →

Community Join

1 / 1 results

community Rejected for the 2nd time for the VDPHL01 Clinical Trials (believe it or not!)

in Chat 12 upvotes 3 weeks ago

The user was rejected from participating in a clinical trial for an extended-release oral Minoxidil due to having rheumatoid arthritis, despite initially being accepted. They had stopped using Dutasteride and Minoxidil to qualify but continued using other treatments like RU58841 and red light therapy.